ReviewRadiology. Imaging cancer2025
Review of Fusariosis in Patients with Hematologic Malignancies.
Review in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural extract-derived compounds for the treatment of hematological diseases through modulation of the bone marrow microenvironment.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hematologic malignancies are among the most common cancers worldwide, with incidence nearly doubling between 1990 and 2019. Compared with the general population, patients with these malignancies are at significantly increased risk for invasive fungal disease (IFD) due to prolonged immunosuppression and neutropenia from chemotherapy, hematopoietic stem cell transplant, or the underlying disease itself. IFD contributes substantially to morbidity and infection-related mortality in this population, with reported mortality rates ranging from 29% to 90%. Among IFD infections, invasive fusariosis is one of the most lethal, with case fatality rates reaching 100% in certain organ systems. It frequently presents as a debilitating, multiorgan infection affecting the skin, bone, central nervous system, and cardiovascular structures. This review highlights the diverse clinical and imaging manifestations of invasive fusariosis in patients with hematologic malignancies, providing a multimodal overview of disease presentations, organ involvement, and treatment approaches based on published cases. Current diagnostic challenges are discussed, along with future strategies aimed at improving early recognition and management. Given the severity and poor outcomes associated with invasive fusariosis, greater awareness and education are essential to improve diagnosis, treatment, and outcomes for this vulnerable population of patients with hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.